Modern approaches to treating acute promyelocytic leukemia

Journal of Clinical Oncology

Volumn 29, Issue 5, 2011, Pages 495-503

  Sanz, Miguel A ^a   Lo Coco, Francesco ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; TAMIBAROTENE; TIOGUANINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYOTOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; BRAIN NEOPLASMS; CYTARABINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRETINOIN;

EID: 79952079063     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.1067     Document Type: Review

References (66)

1. Douer D, Tallman MS: Arsenic trioxide: New clinical experience with an old medication in hematological malignancies. J Clin Oncol 23:2396-2410, 2005 (Pubitemid 46218734)
2. Sanz MA, Lo-Coco F: Arsenic trioxide: Its use in the treatment of acute promyelocytic leukemia. Am J Cancer 5:183-191, 2006 (Pubitemid 46224438)
3. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 101:5328-5335, 2004 (Pubitemid 38481160)
4. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al: Treatment of acute promyelocytic leukemia without ATRA and/or chemotherapy. Ann Oncol 17:131-134, 2006 (Pubitemid 43033852)
5. Mathews V, George B, Lakshmi KM, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107: 2627-2632, 2006
6. Estey E, Garcia-Manero G, Ferrajoli A, et al: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469-3473, 2006
7. Ravandi F, Estey E, Jones D, et al: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504-510, 2009
8. Hu J, Liu YF, Wu CF, et al: Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 106:3342-3347, 2009
9. Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113: 1875-1891, 2009
10. Falini B, Flenghi L, Fagioli M, et al: Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 90:4046-4053, 1997
11. Villamor N, Costa D, Aymerich M, et al: Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PGM3. Am J Clin Pathol 114:786-792, 2000 (Pubitemid 33051916)
12. Gomis F, Sanz J, Sempere A, et al: Immunofluorescent analysis with the anti-PML monoclonal antibody (PG-M3) for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Ann Hematol 83:687-690, 2004 (Pubitemid 39440212)
13. Di Bona E, Avvisati G, Castaman G, et al: Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia. Br J Haematol 108:689-695, 2000 (Pubitemid 30304497)
14. Sanz MA, Martín G, Gonzá lez M, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA Group. Blood 103:1237-1243, 2004 (Pubitemid 38168633)
15. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 94:1192-1200, 1999 (Pubitemid 29380399)
16. Burnett AK, Grimwade D, Solomon E, et al: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial. Blood 93:4131-4143, 1999 (Pubitemid 29279255)
17. Lengfelder E, Reichert A, Schoch C, et al: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 14:1362-1370, 2000 (Pubitemid 30601354)
18. de la Serna J, Montesinos P, Vellenga E, et al: Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395-3402, 2008
19. Sanz MA, Montesinos P, Rayón C, et al: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 115: 5137-5146, 2010
20. Lo-Coco F, Avvisati G, Vignetti M, et al: Frontline treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group. Blood 116: 3171-3179, 2010
21. Fenaux P, Le Deley MC, Castaigne S, et al: Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood 82:3241-3249, 1993 (Pubitemid 23356690)
22. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997 (Pubitemid 27430519)
23. Mandelli F, Diverio D, Avvisati G, et al: Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90:1014-1021, 1997
24. Asou N, Adachi K, Tamura J, et al: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy: Japan Adult Leukemia Study Group. J Clin Oncol 16:78-85, 1998 (Pubitemid 28041582)
25. Sanz MA, Martín G, Rayón C, et al: A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia: PETHEMA Group. Blood 94:3015-3021, 1999 (Pubitemid 29512705)
26. Burnett AK, Hills RK, Grimwade D, et al: Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial. Blood 110:589, 2007 (abstr 589)
27. Rego EM, Kim HT, Ruiz-Arguelles GJ, et al: Improving the treatment outcome of acute promyelocytic leukemia in developing countries through international cooperative network: Report on the International Consortium On Acute Promyelocytic Leukemia Study Group. Blood 114:6, 2009 (abstr 6)
28. Adès L, Chevret S, Raffoux E, et al: Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24:5703-5710, 2006 (Pubitemid 46631312)
29. Barbey JT, Pezzullo JC, Soignet SL: Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615, 2003 (Pubitemid 46594053)
30. Au W-Y, Kumana CR, Lam C-W, et al: Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia Leukemia Res 31: 105-108, 2007
31. Rahman MM, Sengupta MK, Ahamed S, et al: Murshidabad: One of the nine groundwater arsenic affected districts of West Bengal, India - Part 1. Magnitude of contamination and population at risk. Clin Toxicol 43:823-834, 2005
32. Sanz MA, Montesinos P, Vellenga E, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 112: 3130-3134, 2008
33. Bernard J, Weil M, Boiron M, et al: Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood 41:489-496, 1973
34. Avvisati G, Petti MC, Lo Coco F, et al: Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal followup. Blood 100:3141-3146, 2002 (Pubitemid 35217061)
35. Adès L, Sanz M, Chevret S, et al: Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results. Blood 111:1078-1084, 2008 (Pubitemid 351213385)
36. Flanagan SA, Meckling KA: All- transretinoic acid increases cytotoxicity of 1-beta-Darabinofuranosylcytosine in NB4 cells. Cancer Chemother Pharmacol 51:363-375, 2003 (Pubitemid 36649133)
37. Powell BL, Moser B, Stock W, et al: Arsenic trioxide improves event-free survival and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757, 2010
38. Gore SD, Gojo I, Sekeres MA, et al: Single cycle of arsenic trioxide - based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28:1047-1053, 2010
39. Sanz MA, Lo Coco F, Martin G, et al: Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253, 2000 (Pubitemid 30658450)
40. Sanz MA, Vellenga E, Rayón C, et al: All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 104:3490-3493, 2004 (Pubitemid 39564417)
41. Grimwade D, Jovanovic JV, Hills RK, et al: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650-3658, 2009
42. Lo Coco F, Diverio D, Avvisati G, et al: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94: 2225-2229, 1999 (Pubitemid 29467668)
43. Esteve J, Escoda L, Martín G, et al: Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention. Leukemia 21: 446-452, 2007
44. Lo Coco F, Diverio D, Falini B, et al: Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94:12-22, 1999 (Pubitemid 29300129)
45. Grimwade D, Lo Coco F: Acute promyelocytic leukemia: A model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16:1959-1973, 2002
46. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations for the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
47. Diverio D, Rossi V, Avvisati G, et al: Early detection of relapse by prospective reverse transcriptasepolymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial: GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 92:784-789, 1998
48. Breccia M, Diverio D, Noguera NI, et al: Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica 89:29-33, 2004 (Pubitemid 38165852)
49. Avvisati G, Petti MC, Lo Coco F, et al: AIDA: The Italian way of treating acute promyelocytic leukemia (APL) - Final act. Blood 102:142a, 2003 (abstr 487)
50. Asou N, Kishimoto Y, Kiyoi H, et al: A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα-transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59-66, 2007 (Pubitemid 47026819)
51. Shen Z-X, Chen G-Q, Ni J-H, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360, 1997
52. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998 (Pubitemid 28509343)
53. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001 (Pubitemid 32880064)
54. Au WY, Lie AK, Chim CS, et al: Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukemia. Ann Oncol 14: 752-757, 2003 (Pubitemid 36621776)
55. Lazo G, Kantarjian H, Estey E, et al: Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience. Cancer 97:2218-2224, 2003
56. Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia experience with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324, 1999
57. Raffoux E, Rousselot P, Poupon J, et al: Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326-2334, 2003
58. Shigeno K, Naito K, Sahara N, et al: Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: Updated outcomes of the phase II study and postremission therapies. Int J Hematol 82:224-229, 2005
59. Meloni G, Diverio D, Vignetti M, et al: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 90:1321-1325, 1997
60. Thomas X, Dombret H, Cordonnier C, et al: Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation: APL Study Group. Leukemia 14:1006-1013, 2000
61. de Botton S, Fawaz A, Chevret S, et al: Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 23:120-126, 2005
62. Douer D, Hu W, Giralt S, et al: Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 8:132-140, 2003
63. Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia experience with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324, 1999
64. Sanz MA, Labopin M, Gorin NC, et al: Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: A survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transpl 39:461-469, 2007
65. de Botton S, Sanz MA, Chevret S, et al: Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20:35-41, 2006
66. Montesinos P, Díaz-Mediavilla J, Debén G, et al: Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 94:1242-1249, 2009